Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a late-stage clinical biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ announced today that representatives will present and participate at multiple investors conferences in June 2022. Details of the conferences are as follows:

LD Micro Invitational XII

Ken Trbovich, SVP Investor Relations, will make an in-person corporate presentation at 11:00am EDT on June 7, 2022. Advance registration is required to access the webcast, which can be completed by accessing the event website at https://ldinv12.mysequire.com/.

Jefferies Global Healthcare Conference

Cameron Durrant, Chairman & CEO, will provide an in-person corporate presentation at 12:15pm EDT on June 10, 2022. A livestream will be accessible via the link below and a webcast link to a recording of the event will be posted to the “Events and Presentations” section of Humanigen’s investor relations website after the event.

Webcast: https://wsw.com/webcast/jeff240/hgen/1826850 The webcast will be available for 90 days under the “Events & Presentations” section of the company’s website at https://ir.humanigen.com/

Lytham Partners Summer 2022 Conference

Cameron Durrant, Chairman & CEO, will participate in a virtual fireside chat scheduled to be webcast beginning at 9:00am EDT on June 21, 2022.

Webcast: https://wsw.com/webcast/lytham5/hgen/2015304 The webcast will be available for up to 12 months under the “Events & Presentations” section of the company’s website at https://ir.humanigen.com/

About Humanigen

Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), is a late-stage clinical biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’. Lenzilumab is a first-in class antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). Results from preclinical models indicate GM-CSF is an upstream regulator of many inflammatory cytokines and chemokines involved in the cytokine storm. Early in the COVID-19 pandemic, investigation showed high levels of GM-CSF secreting T cells were associated with disease severity and intensive care unit admission. Humanigen’s Phase 3 LIVE-AIR study suggests early intervention with lenzilumab may prevent consequences of a full-blown cytokine storm in hospitalized patients with COVID-19. Humanigen is developing lenzilumab as a treatment for cytokine storm associated with COVID-19 and CD19-targeted CAR-T cell therapies and is also exploring the effectiveness of lenzilumab in other inflammatory conditions such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation, eosinophilic asthma, and rheumatoid arthritis. For more information, visit www.humanigen.com and follow Humanigen on LinkedIn, Twitter, and Facebook.

Forward-Looking Statements

All statements other than statements of historical facts contained in this press release are forward-looking statements. Forward-looking statements reflect management's current knowledge, assumptions, judgment, and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct, and you should be aware that actual events or results may differ materially from those contained in the forward- looking statements. Words such as "will," "expect," "intend," "plan," "potential," "possible," "goals," "accelerate," "continue," and similar expressions identify forward-looking statements, including, without limitation, statements regarding our plans relating to lenzilumab.

Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the risks inherent in our lack of profitability and need for additional capital to grow our business; our dependence on partners to further the development of our product candidates; the uncertainties inherent in the development, attainment of the requisite regulatory authorizations and approvals and launch of any new pharmaceutical product; the outcome of pending or future litigation; and the various risks and uncertainties described in the "Risk Factors" sections of our latest annual and quarterly reports and other filings with the SEC.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You should not rely upon any forward-looking statements as predictions of future events. We undertake no obligation to revise or update any forward-looking statements made in this presentation to reflect events or circumstances after the date hereof, to reflect new information or the occurrence of unanticipated events, to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, in each case, except as required by law.

Humanigen Investor Relations Ken Trbovich Humanigen trbo@humanigen.com 650-410-3206

Grafico Azioni Humanigen (NASDAQ:HGEN)
Storico
Da Mar 2025 a Apr 2025 Clicca qui per i Grafici di Humanigen
Grafico Azioni Humanigen (NASDAQ:HGEN)
Storico
Da Apr 2024 a Apr 2025 Clicca qui per i Grafici di Humanigen